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Abstract
Summary We evaluated the effects of parathyroid hormone
(PTH), pamidronate, or renutrition on osseointegration of
titanium implants in the proximal tibia of rats subject to
prolonged low-protein diets. PTH improved mechanical
fixation, microarchitecture, and increased pull-out strength.
Pamidronate or renutrition had lesser effects. PTH can thus
improve implant osseointegration in protein-malnourished
rats.
Introduction Protein malnutrition impairs implant osseoin-
tegration in rats. PTH and pamidronate prevent deleterious
effects of protein restriction introduced just prior to
implantation. Whether these treatments improve osseointe-
gration after chronic protein deprivation, i.e., in osteopenic
bone at time of implantation, is unknown. We evaluated
effects of PTH, pamidronate, or renutrition on resistance to
pull-out of titanium rods implanted into the rat tibiae
following isocaloric low-protein intake.
Methods Forty-one adult female rats received normal or
isocaloric low-protein diets. Six weeks later, implants
were surgically inserted into proximal tibiae. Following
implantation, rats on low-protein diets were treated with
PTH (1-34), pamidronate, saline vehicle, or normal
protein diets, for another 8 weeks. Tibiae were removed
for micro-computerised tomographic morphometry and
evaluation of pull-out strength.
Results Pull-out strength decreased in rats on isocaloric
low-protein diets compared with normal protein group
(−33.4%). PTH increased pull-out strength in low-
protein group, even compared to controls from the
normal protein group. PTH and pamidronate increased
bone volume/tissue volume, bone-to-implant contact, and
trabecular thickness, whilst trabecular separation was
reduced, with a shift to more plate-like bone surrounding
the implants.
Conclusions PTH reversed the deleterious effects of long-
term protein undernutrition on mechanical fixation and
bone microarchitecture and improved implant osseointegra-
tion more than pamidronate or renutrition, likely through
changes to structure model index.
Keywords Implants . Nutrition . Pamidronate .
Parathyroid hormone . Rodents
Introduction
As the population continues to age, undernutrition and
protein deficiency persist amongst elderly patients living in
nursing homes and in community-dwelling subjects [1–6].
This problem is widely acknowledged and has even driven
the need for assessment tools to diagnose under- or
malnutrition [5, 7–9]. Decreases in dietary protein can be
caused by age-related physiological changes, diseases of
the gastrointestinal tract or of an inflammatory nature,
physical impairment, and psychological as well as psycho-
social issues. It is widely acknowledged that protein
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undernutrition leads to prolonged illness periods [10],
reduced immunity [11–13], and severely negative effects
on the musculoskeletal system [14–16]. It is not surprising
then that a high prevalence of undernutrition is observed in
elderly patients undergoing total hip or total knee arthro-
plasty [17–20] and that the prognosis for these patients is
rather poor as it is difficult to stimulate food intake in these
patients.
In a previous report, we demonstrated that 26 weeks of
an isocaloric low protein diet induces a trabecular bone
volume (BV) loss of around 75% in female rats and 70% in
male rats. This was associated with a diminution of ultimate
strength (or maximal load) in both females and males.
Stiffness and energy were also negatively affected by the
low protein diet in these animals. More recently, we
reported that isocaloric low protein intake, introduced
around the time of surgical implantation, impairs titanium
implant osseointegration in adult female rats. This was
associated with poor bone microarchitecture surrounding
the implant [21].
Both bisphosphonates and parathyroid hormone (PTH)
treatment have been reported to improve implant fixa-
tion, allowing for more durable joint replacements [22–
32]. Indeed, in a recent study, we showed that both PTH
and pamidronate were able to prevent the deleterious
effects of an isocaloric protein restricted diet on bone
microarchitecture close to the implant and on mechanical
fixation in adult female rats [33]. In these experiments,
rats were subject to low protein for only 2 weeks before
the implants were inserted. Immediately following the
implant surgery, PTH or pamidronate was administered for
8 weeks. Both PTH and pamidronate improved the
mechanical fixation, even when compared to animals with
normal protein intake.
It is more likely that a longer duration of protein
malnourishment prior to implantation would more closely
resemble what is often observed in the clinical setting,
with many elderly patients having osteopenia caused by
a long-term lack of sufficient dietary protein. No data has
been reported on whether systemic treatment with
bisphosphonates or PTH (1-34) improve the altered
titanium implant osseointegration observed in prolonged
low protein-induced osteopenic models, or modify the
tridimensional trabecular microarchitecture in the vicinity
of an implant. The effects of renutrition following
implantation in such models have also never been tested.
The aim of the current study was, therefore, to test the
hypothesis that systemic treatments of PTH, bisphosph-
onates, or renutrition are able to augment titanium
implant osseointegration in a rat model of protein-
malnourished-induced osteopenia, a model which closely
resembles what is frequently observed in the clinical
setting of orthopaedic wards.
Materials and methods
Animals and diet
All experimental designs and procedures have received
approval of the Animal Ethics Committee of the Geneva
University Faculty of Medicine. Forty-one 10-month-old
Sprague-Dawley female rats (Charles River Laboratories,
L’Arbresle, France), housed individually at 25°C with a
12:12-h light–dark cycle, were employed. Rats were
strictly pair-fed a laboratory diet provided by Provimi
Kliba AG (Kaiseraugst, Switzerland) containing either
15% or 2.5% casein, 0.8% phosphorus, 1% calcium, 70–
80% carbohydrates, and 5% fat throughout the experi-
mental period. Isocaloric intake by all rats was ensured
by the addition of corn carbohydrate to the low protein
diet, thus providing the same energy intake across all
groups. Demineralised water was available ad libitum.
Since the minimal protein intake in rats necessary to
maintain normal bone homeostasis is 5% [34, 35] and it
is known that casein is not wholly utilisable by rats, a
restriction to 2.5% casein corresponds to a reduction of
more than 50% of the minimum recommended intake, and
a reduction of 50% is often observed in patients who
sustain a hip fracture [36, 37].
Experimental design
One week after an initial adaptation period to a 15% casein-
containing diet, rats were divided into five groups. One
group received a diet containing 15% casein (n=8, 15%
control group), and three groups were placed on a diet
containing 2.5% casein until the end of the study. The final
group received the 2.5% casein diet until the implantation,
after which, they were commenced on 15% casein (n=8,
renutrition group). Six weeks following the beginning of
isocaloric protein restriction (i.e., at week7), a titanium
implant was inserted in each tibia of the animals under
general anaesthesia. We inserted implants into both tibias to
avoid the possibility of disuse or overuse often observed
when only one limb is operated on. Following implantation,
rats from one of the groups receiving 2.5% casein were
injected subcutaneously five times a week with human PTH
(1-34; Eli Lilly and Company, Indianapolis, IN, USA) at a
dose of 40 μg/kg body weight per injection, until the end of
the study (n=8, 2.5% PTH group). This dose has previously
been demonstrated to effectively correct the altered bone
mechanical properties associated with protein deprivation in
rats [33, 38]. It is higher than that used in humans.
Similarly, another of the groups receiving 2.5% casein-
containing diet was treated five times a week during the
first and the fifth weeks post-implantation surgery with
subcutaneous injection of 3-amino-1hydroxypropylidene-1,1-
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bisphosphonate (Pamidronate, Novartis International AG,
Basel, Switzerland) at a dose of 0.6 mg/kg (n=9, 2.5%
pamidronate group). This dose has been shown to prevent
the deleterious effect of isocaloric protein deprivation on
bone strength [39]. Rats in the pamidronate group also
received a subcutaneous injection of vehicle (sodium
chloride, 0.9%, 0.5 ml/kg) five times a week in those weeks
they did not receive pamidronate. All treatments and the
vehicle were injected at the same volume per kilogramme
body weight. The renutrition group was fed with a 15%
casein-containing diet after the implantation as described
above. Finally, the group fed a diet containing 15% casein
(n=8, 15% control group), the renutrition group, and the
remaining group on 2.5% casein diet (n=8, 2.5% control
group) were injected with vehicle (sodium chloride, 0.9%,
0.5 ml/kg) five times a week during the 8 weeks following
implantation. At 8 weeks post-implantation (i.e., at week15),
blood was obtained from all rats by aortic puncture under
general anaesthesia, and animals were killed by an overdose
of ketamine hydrochloride. The tibias were removed for
micro-computerised tomographic (μCT) morphometry and
mechanical testing.
Implants design and preparation
The implants were made from commercially pure titanium
(Institut Straumann AG, Waldenburg, Switzerland), were
1.0 mm in diameter and 4.1 mm long, and were sandblasted
and acid etched on the non-threaded part. The threaded part
was 1.25 mm long (type M1) and remained outside of the
bone, permitting prehension for the pull-out test. This type
of implant was selected as titanium is well tolerated by
bone tissue. The rough surface, fashioned by sandblasting
and acid-etching, ensures good osseointegration. The
implants were cleaned in phosphate-free Deconex® (Borer
Chemie AG, Zuchwil, Switzerland), rinsed in pure water in
an ultrasonic bath, and sterilised with ethylene oxide.
Implantation technique
Animals were anaesthetised by abdominal injections of
ketamine (100 mg/kg) and xylazine (10 mg/kg). The skin of
the bilateral tibial region was shaved and cleaned with 70%
ethanol. We have previously provided a pictorial description
of the implanted region [21]. Under aseptic conditions, a
10-mm incision was made anteriorly to gain access to the
proximal medial section of the tibia metaphysis. The
periosteum was reflected medially. The periosteum in adult
rats is a relatively thin and fragile tissue, which cannot be
replaced around the implant. It was thus left reclined. A
1.0-mm diameter hole was drilled through one of the cortices
with a hand-held drill into which the implant was inserted.
Rotatory speed did not exceed 2,000 rpm, and drilling was
accompanied by profuse saline irrigation to avoid thermal
bone necrosis. The proximal limit of the entry point was
delimited by a virtual line perpendicular to the long axis of
the tibia and crossing the anterior edge of the growth plate
centrally, which is curved in this central region anteriorly and
inferiorly. The second anatomical landmark utilised was a
virtual line passing from the inferior border of the tendinous
insertion on the proximal anterior tibial crest to a medial
tendinous insertion, which most likely corresponds to the pes
anserinus in humans. The point of insertion was halfway
between these two tendinous insertions. We have previously
demonstrated by X-ray examination that employing such
landmarks leads to the implant being in contact with the
trabecular bone of the proximal tibial metaphysis [21], at a
distance of 2 mm distal to the growth plate along the great
axis of the tibia. The implant was inserted perpendicularly to
the surface of the cortical bone on the medial part of the
proximal tibia. The depth of the inserted implant section into
the bone corresponded to the length of the non-threaded
section of the implant (2.85 mm). Only the threaded part
remained outside the bone. The implants were specifically
designed taking into account the X-ray determined dimen-
sions of the proximal tibia in adult female Sprague-Dawley
rats. After insertion of the implant, the skin was sutured
using a 3-0 resorbable polyglactic suture (Vycril®; Ethicon,
Spreintenbach, Switzerland). Postoperative analgesia was
maintained by subcutaneous injection of buprenorphine
(0.06 mg/kg) twice a day for 3 days.
Micro-computerised tomographic (μCT) morphometry
The tibias were carefully excised immediately after death
and frozen at −20°C in plastic bags. The night before μCT
analysis, the bones were thawed slowly at 7° and
maintained at room temperature. During the whole analysis,
they were immersed in saline solution. Parameters of
volume, architecture, and percentage of implant surface in
direct contact with trabecular bone (percentage of attach-
ment, bone-to-implant contact) were studied using μCT
morphometry (μCT 40; Scanco Medical AG, Bassersdorf,
Switzerland). The voxel was 20 μm in all spatial directions.
For penetrating radio-opaque titanium and improving
signal-to-noise ratio, the system was set to 70 kEV with a
350-ms integration time. The number of tomographic
projections was 1,000 projections per 360°. Images were
filtered with a 3-D Gauss philtre with Sigma 1.5 voxels and
then segmented with threshold 1.4 cm−1 for bone (25% of
maximal grey scale value, visually chosen) and threshold
5.8 cm−1 for titanium (attenuation coefficient). Trabecular
bone was analysed on a circular band of 0.5 mm around the
implant (Fig. 2). Relative BV/tissue volume (TV), trabec-
ular number, trabecular thickness, and trabecular separation
were calculated by directly measuring the 3-D distances in
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the trabecular network. Connectivity density based on Euler
number (Conn.D) and the structure model index (SMI)
were calculated. When a bone voxel was in the vicinity (60
µm boundary) of a titanium voxel, this titanium voxel was
classified as “attached surface”. With a distance of 3 voxels
(60µm) from the detected titanium surface, the presence or
absence of bone can be accurately determined (IPL, image
processing language software, available with the µCT 40,
Scanco Medical AG, Bassersdorf, Switzerland). The arte-
facts of the titanium in the CT image prevented us from
analysing the presence of bone at a range closer to the
implant [40, 41]. The number of attached surface voxels
divided by the total number of titanium surface voxels
yielded the percentage bone-to-implant contact. The tridi-
mensional reconstructions obtained were always verified
against the original grey scale images.
Pull-out test
After μCT analysis, implanted tibias were subjected to a
pull-out test. The tibias were held in place on a metal
device by two flat supports 5.6 mm apart. Another metal
piece was screwed onto the threaded, i.e., external part of
the implant and was used to grip the implant during the test.
Pull-out strength was determined as the peak force, i.e., the
maximum failure force, applied to completely loosen the
implant from the bone, and was measured with a servo-
controlled electromechanical system (Instron 1114; Instron
Corp., High Wycombe, UK) with the actuator displacement
speed set at 2 mm/min. Reproducibility was 13.4% (3.3–
22), as evaluated by the mean of the absolute differences
between paired-sample measurements (left/right). A pre-
liminary study showed that freezing the tibias did not alter
pull-out strength values. The mean of the absolute differ-
ences between values obtained before or after freezing
procedure was 12.5% (0.9–35.5). Regression between
values obtained before or after freezing procedure was
characterised by an r2 coefficient of 0.96 [21].
Biochemical assays
Plasma insulin-like growth factor I (IGF-I) was measured
by immunoenzymometric assay, with a kit from Nichols
Institute (San Juan Capistrano, CA, USA) following the
manufacturer’s instructions, and osteocalcin employing a
kit from Biomedical Technologies Inc. (Stoughton, MA,
USA).
Statistical analysis
All results are expressed as mean ±SEM. Significance of
difference was evaluated by analysis of variance (ANOVA)
and post-analysis by Tukey’s honestly significant difference
test (Statistical Package for the Social Sciences (SPSS)
14.0; SPSS Inc., Chicago, IL, USA).
Results
Effect of PTH, pamidronate, or renutrition on pull-out
strength
As previously shown [21, 33], mean pull-out strength
values were decreased in rats fed an isocaloric low protein
diet (−33.4%) compared with animals in the normal protein
group (Fig. 1). Neither pamidronate nor renutrition were
able to increase mechanical fixation above the low protein
control group. PTH treatment, on the other hand, markedly
increased the pull-out strength compared to the control
animals receiving the same diet (2.5%). Pull-out strength
values in the 2.5% PTH group were also higher than in
animals never subject to a low protein diet, i.e., the 15%
control group, as well as compared to the renutrition and
pamidronate-treated groups.
Effect of PTH, pamidronate, or renutrition on μCT
morphometry of the trabecular bone around the implant
To evaluate the effects of PTH, pamidronate, and renu-
trition on pull-out strength, we analysed the trabecular bone
microarchitecture around the implant and bone-to-implant
contact. BV/TV values and bone-to-implant contact were
lower in the low protein group compared to the normal
protein group (Figs. 2, 3, and 4). Both PTH and
pamidronate treatments increased BV/TV values and
bone-to-implant contact compared with the low-protein
intake control group and the renutrition group. Systemic
administration of PTH or pamidronate under protein
restriction increased BV/TV and bone-to-implant contact
to values higher than those observed in control animals
with normal protein intake. Finally, renutrition was unable
to increase BV/TV or bone-to-implant contact compared to
the low-protein control group.
Protein restriction, PTH, and pamidronate affected other
parameters of the trabecular bone architecture in the vicinity
of the implant (Table 1). A significant increase of trabecular
number was noted in the 2.5% pamidronate group compared
with the 15% and the 2.5% controls. Isocaloric protein
restriction was associated with lower values of trabecular
thickness when compared to the normal protein intake
control group. PTH and pamidronate treatments increased
trabecular thickness when compared to the low-protein
control animals, the normal protein control animals, or the
animals in the renutrition group. Accordingly, similar
changes were noted for trabecular separation when compared
to 2.5% and 15% control groups. This was associated with
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alterations of the trabecular structure, as illustrated by
changes in the SMI. Protein restriction induced a shift
toward more rod-like bone microstructures, although more
plate-shaped bone was observed in the animals treated with
PTH or pamidronate compared with 2.5% controls and the
renutrition group. This effect was stronger under PTH
treatment, with a decrease of SMI even when compared to
the values obtained with pamidronate or in the normal
protein control group. A non-significant decrease of connec-
tivity density was noted in the low-protein-fed animals. This
value was higher with pamidronate treatment, when com-
pared to animals in the renutrition group.
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Fig. 1 Effects of systemic pamidronate or parathyroid hormone
(PTH) treatment under isocaloric low protein intake or renutrition on
pull-out strength of titanium implant inserted in the proximal tibial
metaphysis of adult female rats 8 weeks after surgery, i.e., after
14 weeks of protein restriction. Treatments with pamidronate or PTH
and renutrition were started immediately after implantation. Values are
means±SEM, asterisk corresponds to p<0.05 vs the control normal
protein intake group, degrees corresponds to p<0.05% vs the control
low protein intake group, number sign corresponds to p<0.05% vs the
renutrition group, and ampersand corresponds to p<0.05% vs the
pamidronate low protein group, as evaluated by analysis of variance
and post-analysis by Tukey’s honestly significant difference test
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Fig. 2 Microtomographic
morphometry by microcom-
puted tomography. Microtomo-
graphic tridimensional
reconstruction of the trabecular
bone around titanium implants
at 8 weeks after implantation.
The two upper panels are from
samples in the control groups
(15% control and 2.5% control),
and the three lower ones are
from samples in the pamidronate
and parathyroid hormone (PTH)
low protein intake groups (2.5%
pamidronate and 2.5% PTH)
and renutrition group. Relative
bone volume (BV/TV) around
titanium implants and bone-
to-implant contact (BIC) of the
corresponding samples are
indicated
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Effect of isocaloric protein restriction and renutrition
on IGF-I, osteocalcin, and on body weight
Isocaloric low protein intake decreased plasma IGF-I levels
(Table 2) consistent with previously shown data [21, 34, 35,
42]. Protein restriction was associated with lower body
weight, despite strict pair-feeding with isocaloric diets.
Renutrition increased plasma IGF-I levels and body weight
when compared to the three other groups subjected to
protein restriction throughout the entire study.
Isocaloric protein restriction was not associated with
significant changes of osteocalcin levels, when compared to
the 15% controls and the renutrition groups (Table 2).
Treatment with pamidronate was associated with a reduc-
tion of osteocalcin levels when compared with the 2.5%
control group and the renutrition group. PTH induced
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Fig. 3 Effects of systemic pamidronate or parathyroid hormone
treatment under isocaloric low protein intake, or renutrition on relative
bone volume (BV/TV) around titanium implants in the proximal tibial
metaphysis of adult female rats 8 weeks after surgery. Values are
means±SEM, asterisks corresponds to p<0.05 vs the control normal
protein intake group, degrees corresponds to p<0.05% vs the control
low protein intake group, and number sign corresponds to p<0.05%
vs the renutrition group, as evaluated by analysis of variance and post-
analysis by Tukey’s honestly significant difference test
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Fig. 4 Effects of systemic pamidronate or parathyroid hormone
treatment under isocaloric low protein intake or renutrition on bone-
to-implant contact in the proximal tibial metaphysis of adult female
rats 8 weeks after surgery. Values are means±SEM, asterisk
corresponds to p<0.05 vs the control normal protein intake group,
degrees corresponds to p<0.05% vs the control low protein intake
group, and number sign corresponds to p<0.05% vs the renutrition
group, as evaluated by analysis of variance and post-analysis by
Tukey’s honestly significant difference test
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significant higher levels of osteocalcin when compared to
the animals treated with pamidronate.
Discussion
We have previously shown that an isocaloric low protein
diet induces increased bone resorption and depressed
bone formation, resulting in bone loss in rats [34]. The
results of the current study indicate that a prolonged
isocaloric low protein intake also results in deleterious
effects on titanium implant osseointegration. Systemic
treatment with PTH (1-34) markedly increased the
mechanical fixation of the implant under protein restric-
tion. Interestingly, PTH treatment in addition to a low
protein diet was able to increase the pull-out strength
needed to completely loosen the implants, even compared
to control animals with normal protein intake. We also
observed that PTH treatment significantly improved bone-
to-implant contact and induced a higher relative BV in the
vicinity of the implants. PTH also induced an increase in
trabecular thickness, a decrease in trabecular separation,
and a shift to more plate-like bone structures, which have
all been shown to improve some of the biomechanical
properties that aid in the prevention of bone fragility and
decrease fracture risk [43]. It is also likely, therefore, that
such improvements in these properties contribute to the
osseointegration of titanium implants. It should be noted
Table 1 Effects of pamidronate or parathyroid hormone under isocaloric dietary protein restriction or renutrition on bone architecture around the
titanium implant
Casein (%) 15 2.5
Treatment Controls (n=8) Controls (n=8) Pamidronate (n=9) PTH (n=8) Renutrition (n=8)
Tb.N (1/mm) 4.85±0.26 4.30±0.21 5.37±0.17*° 5.09±0.19 4.51±0.18
Tb.Th (μm) 118.9±5.5 105.6±3.8* 152.5±4.4*°# 150.1±6.5*°# 114.5±3.6
Tb.Sp (mm) 0.250±0.020 0.274±0.015 0.197±0.011°# 0.203±0.013°# 0.267±0.015
SMI 0.97±0.22 1.47±0.16 0.01±0.42°# −1.07±0.32*°#& 1.58±0.09
Conn.D. 41.22±5.28 31.23±5.29 45.96±3.51# 37.20±4.31 27.59±3.77
Values are means±SEM. Results are trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), structure model index
(SMI), and connectivity density based on Euler number (Conn.D.). SMI is an estimate of the rod characteristics of trabecular bone (0 value=
purely plate-shaped bone, 3 value=purely rod-like bone, negative values indicate a solid mass with only few holes in it). Isocaloric protein
restriction was started 6 weeks before bilateral tibial insertion of titanium implants. After surgery, rats were treated with daily subcutaneous
injections of a saline vehicle (control), pamidronate, or human parathyroid hormone (PTH), as specified in the “Materials and methods”. Another
group received a diet containing 2.5% casein until the implantation; after the surgery, animals in this group received a diet containing 15% casein
and were treated with saline vehicle (renutrition group). Animals were sacrificed at 8 weeks after implantation
asterisk corresponds to p<0.05 vs the control normal protein intake group; degrees corresponds to p<0.05% vs the control low protein intake
group; number sign corresponds to p<0.05% vs the renutrition group; ampersand corresponds to p<0.05% vs the pamidronate low protein group
(as evaluated by ANOVA and post-analysis by Tukey’s HSD test)
Table 2 Effects of isocaloric protein restriction on insulin-like growth factor I, osteocalcin plasma levels, and change in body weight
Casein (%) 15 2.5
Treatment Controls (n=8) Controls (n=8) Pamidronate (n=9) PTH (n=8) Renutrition (n=8)
IGF-I (ng/mL) 687.1±35.8 480.7±20.2*# 427.9±17.7*# 444.3±26.3*# 678.3±29.8
Osteocalcin (nmol/L) 10.8±0.5 11.9±0.9 6.7±0.2*°# 12.6±0.7& 10.3±0.5
Δ Weight (g) −13.8±8.6 −70.1±8.2*# −66.4±6.0*# −71.1±7.4*# −22.6±5.5
Values are means±SEM. Isocaloric protein restriction was started 6 weeks before bilateral tibial insertion of a titanium implant. After surgery, rats
were treated with daily subcutaneous injections of a saline vehicle (control), pamidronate, or human parathyroid hormone (PTH), as specified in
“Materials and methods”. Another group received a diet containing 2.5% casein until the implantation; after the surgery, animals in this group
received a diet containing 15% casein (renutrition group) and were treated with saline vehicle. Determinations were performed 8 weeks after
implantation, when rats were killed. Values are mean insulin-like growth factor I plasma levels (IGF-I) and mean difference of weight from the
beginning of the experiment (Δ weight)
asterisk corresponds to p<0.05 vs the control normal protein intake group; degrees corresponds to p<0.05% vs the control low protein intake
group; number sign corresponds to p<0.05% vs the renutrition group; ampersand corresponds to p<0.05% vs the low protein group treated with
pamidronate (as evaluated by ANOVA and post-analysis by Tukey’s HSD test)
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that PTH treatment may have a greater anabolic effect
on bone in rats than in humans, as an increased mean
wall thickness has been reported in rats given intermit-
tent PTH treatment [44], whereas this parameter is
unchanged in humans [45]. Treatment with pamidronate,
an inhibitor of bone resorption, was also able to
effectively prevent the negative impact of isocaloric
protein restriction on bone architecture surrounding the
titanium implants. Pamidronate induced an increase in
relative BV, bone-to-implant contact, trabecular number,
and trabecular thickness, even when compared to control
animals with normal protein intake. Improved trabecular
separation and a shift to more plate-like trabecular
structures were also noted when compared to control
animals on an isocaloric low protein diet. However, these
positive morphometric effects of pamidronate were not
associated with significant increases in the pull-out
strength. Finally, renutrition implemented immediately
following implantation was unable to improve mechanical
fixation, relative BV, bone-to-implant contact, or any of
the other measured parameters of trabecular bone micro-
architecture around the titanium implant, despite com-
pletely correcting the low IGF-I levels induced by the low
protein diet. It should also be noted that in other studies
performed in our group, it has been reported that dietary
protein intake in patients who sustained hip fractures
averaged between 0.6 and 0.7 g/kg of body weight [46,
47], whereas the recommended daily allowance for elderly
adults is 1–1.2 g/kg of body weight [48], with anything
below 0.8 g/kg of body weight being considered to
represent protein undernutrition [14]. Furthermore,
attempts to improve protein intake have been performed
with insufficient success [36, 49]. It is very difficult to
change the habits of both the patients and the caretakers.
In addition, following dental implant procedures, mastic-
ular function is often decreased, and maintaining food
intake, let alone increasing it in order to obtain higher
dietary protein, is rarely possible. In our opinion, there is
no doubt that the best case scenario would be to improve
protein intake post-surgery; however, it remains to be the
situation, even within care-facilities, and such intervention
is therefore not common practise. As such, post-surgical
protein malnutrition remains a problem. This, taken with
the results of the current study, highlights the need to look
to treatments to improve osseointegration following
implantation. It should be noted that one limitation of
the current study is that while casein is a very common
protein source for rats, it is not wholly digestible or
utilisable by rats [50], and therefore, the rats receiving the
low protein diet may actually be receiving less than 50%
of the minimal requirement for protein.
The changes in bone remodelling previously observed
with protein deprivation [34] were also associated with
decreased IGF-I concentrations and a resistance to IGF-I at
the level of the target organs. In the present study,
decreased plasma IGF-I was found in all animals exposed
to the isocaloric low protein diet; however, IGF-I levels
returned to normal in the renutrition group only. This
confirms the low IGF-I levels under a low protein diet.
Such malnutrition may also interfere with the process of
osseointegration, in which both bone resorption and
formation are implicated [51, 52].
A recent study in animals indicated that treatments with
PTH or pamidronate immediately following implantation
fully prevented the deleterious effects associated with an
isocaloric low protein diet commenced 2 weeks prior to
implantation. Both treatments significantly increased pull-
out strength in animals fed an isocaloric low protein diet,
and PTH even induced a higher mechanical fixation when
compared to animals with normal protein intake [33]. The
current results establish that PTH treatment provides
beneficial effects following long-term protein deprivation,
a condition which more closely mimics the nutritional
status of many elderly patients in orthopaedic wards
undergoing total hip or knee arthroplasty [17–20]. The
increases seen in bone-to-implant contact and relative BV
following PTH treatment contribute to the positive effects
of PTH on implant fixation after long-term low protein diet.
We have previously shown that bone-to-implant contact is a
strong predictor of pull-out strength [21]. It should be
noted, however, that relative BV and bone-to-implant
contact were not significantly different between PTH and
pamidronate treatments, yet the pull-out strength values
with PTH were higher than those obtained with pamidro-
nate. Linear regression analysis indicates that there is a
relationship between SMI and pull-out strength, character-
ised by an r2 value of 65% (Fig. 5). SMI characterises the
form of the trabecular structure, describing whether this
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Fig. 5 Regression analysis between structure model index (SMI) and
pull-out strength. Regression analysis revealed that SMI is a good
predictor of pull-out strength, with an r2 value of 0.651: Y=2.249−
0.038×X; R2=0.651
964 Osteoporos Int (2010) 21:957–967
bone takes on rod-like shapes or more plate-like structures
and was the only microstructural parameter which predicted
pull-out strength. This is the first time a relationship
between SMI and implant pull-out strength has been
reported and may indeed underlie the interesting differences
in pull-out strength observed between the PTH-treated and
alendronate-treated rats. These results do not rule out the
involvement of other factors, including enhanced material
level properties and/or an increase in bone ingrowth into the
microscopic pits of the textured titanium surface with PTH
treatment. It is possible that this would generate a stronger
bone interlacing and mechanical coupling at the interface.
The nanometric pits on the titanium surface are largely
below the resolution power of the µCT. The only technique
available for such a tridimensional analysis would be a
synchrotron [53], which was not available for this study.
Another possible explanation for the less potent effects
of pamidronate under long-term protein deprivation is
linked to the observation that isocaloric protein restriction
is initially able to transiently decrease both bone resorption
and bone formation [35]. Decreased bone formation may be
the dominant feature of the changes in bone remodelling
seen during the first weeks of protein undernutrition. This is
also consistent with the strong positive effects of PTH
treatment under such a diet, promoting bone formation into
the microscopic pits on the titanium surface and thus
inducing stronger mechanical fixation of the implant. With
bone formation already depressed by protein deprivation,
pamidronate, whose effects are primarily to inhibit bone
resorption, is unable to reverse this deleterious effect [34].
However, our results regarding osteocalcin levels do not
support this hypothesis. Osseointegration represents a
complex interaction in which local bone biology plays a
key role. This could contribute to the difficulty of drawing
explanations based on biochemical markers reflecting
general bone metabolism.
Finally, renutrition was unable to correct the deleterious
effects of protein restriction on implant fixation, bone-to-
implant contact, and the other tested parameters of
trabecular bone microarchitecture, even when applied over
a longer period (8 weeks) than protein deprivation
(6 weeks). It should be noted, however, that plasma IGF-I
was increased by protein renutrition, mimicking observa-
tions seen in clinical studies [54, 55]. This lack of effect of
renutrition on osseointegration, even with increased IGF-I
plasma levels (when compared to the other low protein
groups), was unexpected. Indeed, in a previous study,
essential amino acid supplements, at doses, which effec-
tively increased plasma IGF-I, corrected bone strength via
an increase in cortical thickness [42]. Taken together, these
results combined with the current data support the
hypothesis that essential amino acids may be more
efficacious than protein repletion alone. Another possibility
is that IGF-I production stimulated by protein intake affects
trabecular bone less than it does cortical bone.
In conclusion, in an experimental model of prolonged
isocaloric dietary protein restriction, we have shown, for the
first time, that systemic treatment with PTH is able to
completely reverse the negative effects of long-term protein
undernutrition on titanium implant osseointegration. In
animals fed a low protein diet, mechanical fixation was
significantly increased by PTH treatment, even when
compared with the animals fed a normal protein diet. These
positive effects were associated with increased bone-to-
implant contact and with beneficial changes in the
trabecular structure around the implant, including increased
relative BV, thicker trabeculae, diminished trabecular
separation, and a more plate-like trabecular network.
Pamidronate treatment also significantly increased bone-
to-implant contact and relative BV, even when compared
with animals in the normal protein group. Positive changes
in other parameters of trabecular bone microarchitecture
around the implant were also noted; however, a significant
corresponding increase in the mechanical fixation of the
implant was not observed, while renutrition was unable to
improve bone microarchitecture or pull-out strength values.
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